Acalabrutinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Acalabrutinib: From Mantle Cell Lymphoma to Familial Non-Hodgkin Lymphoma
One-Sentence Summary
Acalabrutinib (Calquence®) is a selective, second-generation BTK inhibitor approved by the US FDA for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), though it has not been registered in Singapore. The TxGNN model predicts it may be effective for Familial Non-Hodgkin Lymphoma, with 20 clinical trials and 20 publications currently supporting this direction. Evidence is rated L2, based on multiple completed Phase 2 trials in closely related B-cell NHL subtypes.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — US FDA-approved; not registered in Singapore |
| Predicted New Indication | Lymphoma, Non-Hodgkin, Familial |
| TxGNN Prediction Score | 97.64% |
| Evidence Level | L2 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Acalabrutinib irreversibly binds to the Cys481 residue of Bruton's tyrosine kinase (BTK), blocking downstream B-cell receptor (BCR) signaling — specifically the NF-κB, PI3K-AKT, and MAPK cascades — that malignant B cells depend on for survival and proliferation. Compared to first-generation ibrutinib, acalabrutinib has substantially reduced off-target inhibition of EGFR and ITK, which translates to lower rates of atrial fibrillation and bleeding events in clinical practice.
Familial non-Hodgkin lymphoma encompasses hereditary predispositions to B-cell lymphoma subtypes including MCL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and marginal zone lymphoma. Since virtually all B-cell NHL subtypes share BCR/BTK signaling as a core oncogenic driver, the mechanistic rationale for BTK inhibition extends naturally to both sporadic and familially predisposed cases. Acalabrutinib has already demonstrated efficacy across multiple NHL subtypes in completed Phase 2 trials — in DLBCL, follicular lymphoma, and indolent B-cell NHL — collectively forming strong class-level support for the TxGNN prediction.
Currently, detailed mechanism of action data specific to the familial NHL context is not available in the evidence pack. However, based on acalabrutinib's well-established BTK dependency across the B-cell NHL spectrum and its existing FDA approvals within that same spectrum, the prediction is biologically coherent and is substantiated by robust Phase 2 clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03899337 | Phase 2 | Recruiting | 105 | Randomized comparison of Acalabrutinib + CHOP-R vs CHOP-R alone in newly diagnosed Richter's Syndrome (CLL transforming to aggressive NHL) |
| NCT04094142 | Phase 2 | Completed | 66 | Acalabrutinib + rituximab + lenalidomide (R2A) in relapsed/refractory aggressive B-cell NHL; ORR and CR rate as primary/secondary endpoints |
| NCT03623373 | Phase 2 | Completed | 13 | Acalabrutinib + bendamustine/rituximab followed by cytarabine/rituximab in treatment-naïve MCL; safety and complete response data |
| NCT04257578 | Phase 1/2 | Active, Not Recruiting | 23 | Acalabrutinib + axicabtagene ciloleucel (anti-CD19 CAR-T) in B-cell lymphoma; evaluating safety and potential synergy of BTKi + immunotherapy |
| NCT04546620 | Phase 2 | Active, Not Recruiting | 453 | Randomized molecular-guided addition of Acalabrutinib to R-CHOP in previously untreated CD20+ DLBCL |
| NCT04502394 | Phase 1/2 | Unknown | 84 | KRT-232 (MDM2 inhibitor) combined with Acalabrutinib in R/R DLBCL or CLL; safety, tolerability, and PK profiling |
| NCT04883437 | Phase 2 | Recruiting | 49 | Acalabrutinib + obinutuzumab in previously untreated, low-tumor-burden follicular lymphoma and other indolent NHL |
| NCT02362035 | Phase 1/2 | Completed | 161 | Acalabrutinib + pembrolizumab in hematologic malignancies; safety, pharmacodynamics, and efficacy across B-cell malignancy subtypes |
| NCT02180711 | Phase 1/2 | Active, Not Recruiting | 113 | Acalabrutinib alone or + rituximab (± lenalidomide) in R/R follicular lymphoma and marginal zone lymphoma |
| NCT04002947 | Phase 2 | Recruiting | 132 | Acalabrutinib + DA-EPOCH-R or R-CHOP in untreated aggressive B-cell lymphoma including DLBCL; assessing cure rate improvement |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29241979 | 2018 | Phase 2 Single-Arm Trial | The Lancet | ACE-LY-004: Acalabrutinib monotherapy in R/R MCL; ORR 81%, median DOR 17.1 months — the pivotal study underpinning FDA accelerated approval |
| 40311141 | 2025 | Phase 2 Trial | J Clin Oncol | Acalabrutinib + bendamustine-rituximab vs BR alone in treatment-naïve MCL; progression-free and overall survival outcomes |
| 38781315 | 2024 | Phase 2 Trial | Blood Advances | Acalabrutinib + venetoclax + rituximab (AVR) in treatment-naïve MCL; 95.2% of 21 patients completed induction at 2-year analysis |
| 38555311 | 2024 | Phase 2 Trial | Nature Communications | R2A (acalabrutinib + lenalidomide + rituximab) in R/R aggressive B-cell NHL; ORR as primary endpoint, synergistic BTKi + immunomodulatory mechanism explored |
| 37470152 | 2024 | Phase 2 Trial | Haematologica | Final results and overall survival from acalabrutinib monotherapy in R/R MCL including patients with poor prognostic factors |
| 41289154 | 2026 | Phase 2 Trial | Blood Advances | MRD-guided acalabrutinib + lenalidomide + rituximab or obinutuzumab in frontline MCL; undetectable MRD (uMRD6) as primary endpoint |
| 40775236 | 2025 | Phase 2 Trial | Nature Communications | Frontline acalabrutinib + lenalidomide + rituximab in advanced-stage follicular lymphoma with high tumor burden; CR rate at 30 months |
| 36029036 | 2023 | Review | Br J Haematol | Updated review of BTKi resistance mechanisms in CLL and NHL, covering both tumour-intrinsic mutations and microenvironment-driven bypass pathways relevant to acalabrutinib |
| 35266562 | 2022 | Review | Am J Hematol | Comprehensive 2022 MCL update: molecular pathogenesis, prognostication (TP53, NSD2, SOX-11), and treatment landscape including BTK inhibitor strategies |
| 29209955 | 2018 | Drug Review | Drugs | Acalabrutinib first global approval: development milestones from Phase 1 through FDA accelerated approval, Phase 3 trial overview |
Singapore Market Information
Acalabrutinib currently holds no HSA registration in Singapore (0 active licences). The drug has received US FDA approval for relapsed/refractory MCL (October 2017, accelerated) and CLL/SLL (November 2019), and EMA approval under the brand name Calquence®. A formal Singapore registration application has not yet been pursued. Market access would require submission of a full dossier to the Health Sciences Authority (HSA) under the New Drug Application pathway.
Cytotoxicity
Acalabrutinib is an antineoplastic agent used in the treatment of blood cancers (MCL, CLL/SLL), and is classified as a targeted kinase inhibitor.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — selective covalent BTK kinase inhibitor; does not directly damage DNA or inhibit cell division non-specifically |
| Myelosuppression Risk | Low to moderate (neutropenia reported in clinical trials; significantly less haematotoxic than conventional cytotoxic chemotherapy) |
| Emetogenicity Classification | Low (oral capsule formulation; nausea is generally mild and manageable) |
| Monitoring Items | CBC with differential (at baseline and periodically), liver function (ALT/AST), renal function; monitor for bruising, bleeding, and opportunistic infections (including fungal) |
| Handling Protection | Not classified as a conventional hazardous cytotoxic agent; follow institutional protocols for oral oncology agents and safe handling of antineoplastics |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Acalabrutinib's 97.64% TxGNN prediction score for familial NHL is mechanistically well-grounded — BTK inhibition directly targets the BCR signalling axis that drives all major B-cell NHL subtypes, and multiple completed Phase 2 trials confirm antitumour activity across the NHL spectrum, supporting an L2 evidence rating. However, familial NHL-specific clinical data are absent, and Singapore regulatory approval does not yet exist.
To proceed, the following is needed:
- Full safety profile: Retrieve Singapore HSA-equivalent labelling or FDA prescribing information (DB11703) for complete warnings, contraindications, and drug interactions — currently a blocking data gap
- Mechanism of action documentation: Obtain full MOA data from DrugBank to support any regulatory submission or clinical protocol
- Familial NHL-specific evidence: Determine whether familial NHL patients are enrolled in existing BTK inhibitor trials; request subgroup analyses or consider a dedicated registry study
- Singapore regulatory pathway: Evaluate HSA requirements for a New Drug Application in the NHL indication; assess whether existing US/EU approvals support an abridged review route
- Local epidemiology: Assess the prevalence of familial NHL in Singapore and identify whether local genetic counselling infrastructure can support eligibility screening and germline testing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.